Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.

Messick TE, Smith GR, Soldan SS, McDonnell ME, Deakyne JS, Malecka KA, Tolvinski L, van den Heuvel APJ, Gu BW, Cassel JA, Tran DH, Wassermann BR, Zhang Y, Velvadapu V, Zartler ER, Busson P, Reitz AB, Lieberman PM.

Sci Transl Med. 2019 Mar 6;11(482). pii: eaau5612. doi: 10.1126/scitranslmed.aau5612.

PMID:
30842315
2.

Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation.

Coyne AN, Yamada SB, Siddegowda BB, Estes PS, Zaepfel BL, Johannesmeyer JS, Lockwood DB, Pham LT, Hart MP, Cassel JA, Freibaum B, Boehringer AV, Taylor JP, Reitz AB, Gitler AD, Zarnescu DC.

Hum Mol Genet. 2015 Dec 15;24(24):6886-98. doi: 10.1093/hmg/ddv389. Epub 2015 Sep 18.

3.
4.

Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function.

Cassel JA, McDonnell ME, Velvadapu V, Andrianov V, Reitz AB.

Biochimie. 2012 Sep;94(9):1974-81. doi: 10.1016/j.biochi.2012.05.020. Epub 2012 May 29.

5.

Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ.

Cassel JA, Ilyin S, McDonnell ME, Reitz AB.

Bioorg Med Chem. 2012 Jun 1;20(11):3609-14. doi: 10.1016/j.bmc.2012.03.067. Epub 2012 Apr 11.

PMID:
22546203
6.

Development of a novel nonradiometric assay for nucleic acid binding to TDP-43 suitable for high-throughput screening using AlphaScreen technology.

Cassel JA, Blass BE, Reitz AB, Pawlyk AC.

J Biomol Screen. 2010 Oct;15(9):1099-106. doi: 10.1177/1087057110382778. Epub 2010 Sep 20.

7.

Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis.

Pawlyk AC, Cassel JA, Reitz AB.

Curr Pharm Des. 2010;16(18):2053-73. Review.

PMID:
20370663
8.

Design and Synthesis of Imidazopyrimidine Derivatives as Potent iNOS Dimerization Inhibitors.

Chu GH, Le Bourdonnec B, Gu M, Ajello CW, Leister LK, Sellitto I, Cassel JA, Tuthill PA, O' Hare H, Dehaven RN, Dolle RE.

Open Med Chem J. 2009 Nov 18;3:8-13. doi: 10.2174/1874104500903010008.

9.

Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.

Sellitto I, Le Bourdonnec B, Worm K, Goodman A, Savolainen MA, Chu GH, Ajello CW, Saeui CT, Leister LK, Cassel JA, Dehaven RN, Labuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):387-91. doi: 10.1016/j.bmcl.2009.10.062. Epub 2009 Oct 17.

PMID:
19919895
10.

Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.

Chu GH, Saeui CT, Worm K, Weaver DG, Goodman AJ, Broadrup RL, Cassel JA, DeHaven RN, LaBuda CJ, Koblish M, Brogdon B, Smith S, Le Bourdonnec B, Dolle RE.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5931-5. doi: 10.1016/j.bmcl.2009.08.063. Epub 2009 Aug 21.

PMID:
19736007
11.

Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).

Le Bourdonnec B, Windh RT, Leister LK, Zhou QJ, Ajello CW, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE.

J Med Chem. 2009 Sep 24;52(18):5685-702. doi: 10.1021/jm900773n.

PMID:
19694468
12.

Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.

Worm K, Weaver DG, Green RC, Saeui CT, Dulay DM, Barker WM, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Brogdon BL, Smith SA, Dolle RE.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5004-8. doi: 10.1016/j.bmcl.2009.07.057. Epub 2009 Jul 12.

PMID:
19646869
13.

CB2 selective sulfamoyl benzamides: optimization of the amide functionality.

Goodman AJ, Ajello CW, Worm K, Le Bourdonnec B, Savolainen MA, O'Hare H, Cassel JA, Stabley GJ, Dehaven RN, Labuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):309-13. doi: 10.1016/j.bmcl.2008.11.091. Epub 2008 Nov 27.

PMID:
19091565
14.

Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).

Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE.

J Med Chem. 2008 Oct 9;51(19):5893-6. doi: 10.1021/jm8008986. Epub 2008 Sep 13.

PMID:
18788723
15.

Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.

Kumar V, Guo D, Marella M, Cassel JA, Dehaven RN, Daubert JD, Mansson E.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71. doi: 10.1016/j.bmcl.2007.11.116. Epub 2007 Dec 4.

PMID:
18487043
16.

Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.

Worm K, Zhou QJ, Saeui CT, Green RC, Cassel JA, Stabley GJ, DeHaven RN, Conway-James N, LaBuda CJ, Koblish M, Little PJ, Dolle RE.

Bioorg Med Chem Lett. 2008 May 1;18(9):2830-5. doi: 10.1016/j.bmcl.2008.04.006. Epub 2008 Apr 7.

PMID:
18430570
17.

Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.

Le Bourdonnec B, Barker WM, Belanger S, Wiant DD, Conway-James NC, Cassel JA, O'Neill TJ, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2006-12. doi: 10.1016/j.bmcl.2008.01.106. Epub 2008 Feb 2.

PMID:
18313920
18.

Discovery of a series of aminopiperidines as novel iNOS inhibitors.

Le Bourdonnec B, Leister LK, Ajello CA, Cassel JA, Seida PR, O'Hare H, Gu M, Chu GH, Tuthill PA, DeHaven RN, Dolle RE.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43. Epub 2007 Oct 25.

PMID:
18024030
19.

Novel malonamide derivatives as potent kappa opioid receptor agonists.

Chu GH, Gu M, Cassel JA, Belanger S, Graczyk TM, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE.

Bioorg Med Chem Lett. 2007 Apr 1;17(7):1951-5. Epub 2007 Jan 25.

PMID:
17307360
20.

Novel phenylamino acetamide derivatives as potent and selective kappa opioid receptor agonists.

Chu GH, Gu M, Cassel JA, Belanger S, Stabley GJ, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE.

Bioorg Med Chem Lett. 2006 Feb;16(3):645-8. Epub 2005 Nov 2.

PMID:
16263278
21.

Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints.

Chu GH, Gu M, Cassel JA, Belanger S, Graczyk TM, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5114-9. Epub 2005 Oct 3.

PMID:
16203140
22.

[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists.

Cassel JA, Daubert JD, DeHaven RN.

Eur J Pharmacol. 2005 Sep 27;520(1-3):29-36.

PMID:
16165125
23.

Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.

Le Bourdonnec B, Ajello CW, Seida PR, Susnow RG, Cassel JA, Belanger S, Stabley GJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE.

Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52.

PMID:
15863335
24.

Pharmacological characterization of human kappa/mu opioid receptor chimeras that retain high affinity for dynorphin A.

DeHaven RN, Mansson E, Daubert JD, Cassel JA.

Curr Top Med Chem. 2005;5(3):303-13. Review.

PMID:
15857313
25.

Amino acid conjugates as kappa opioid receptor agonists.

Kumar V, Guo D, Daubert JD, Cassel JA, DeHaven RN, Mansson E, DeHaven-Hudkins DL, Maycock AL.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1279-82.

PMID:
15713370
26.

Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists.

Kumar V, Guo D, Cassel JA, Daubert JD, Dehaven RN, Dehaven-Hudkins DL, Gauntner EK, Gottshall SL, Greiner SL, Koblish M, Little PJ, Mansson E, Maycock AL.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1091-5.

PMID:
15686919
27.

Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists.

Tuthill PA, Seida PR, Barker W, Cassel JA, Belanger S, DeHaven RN, Koblish M, Gottshall SL, Little PJ, DeHaven-Hudkins DL, Dolle RE.

Bioorg Med Chem Lett. 2004 Nov 15;14(22):5693-7.

PMID:
15482950
28.

(4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands.

Dolle RE, Machaut M, Martinez-Teipel B, Belanger S, Cassel JA, Stabley GJ, Graczyk TM, DeHaven RN.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3545-8.

PMID:
15177470
29.

trans-3,4-dimethyl-4-(3-carboxamidophenyl)piperidines: a novel class of micro-selective opioid antagonists.

Le Bourdonnec B, Belanger S, Cassel JA, Stabley GJ, DeHaven RN, Dolle RE.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4459-62.

PMID:
14643346
30.

Structure-activity relationships of dynorphin a analogues modified in the address sequence.

Schlechtingen G, DeHaven RN, Daubert JD, Cassel JA, Chung NN, Schiller PW, Taulane JP, Goodman M.

J Med Chem. 2003 May 22;46(11):2104-9.

PMID:
12747782
31.

Solid-phase synthesis of substituted alkynes using the Nicholas reaction.

Cassel JA, Leue S, Gachkova NI, Kann NC.

J Org Chem. 2002 Dec 27;67(26):9460-3.

PMID:
12492355
32.

Antipruritic and antihyperalgesic actions of loperamide and analogs.

DeHaven-Hudkins DL, Cowan A, Cortes Burgos L, Daubert JD, Cassel JA, DeHaven RN, Kehner GB, Kumar V.

Life Sci. 2002 Oct 25;71(23):2787-96.

PMID:
12383884
33.

Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands.

Rew Y, Malkmus S, Svensson C, Yaksh TL, Chung NN, Schiller PW, Cassel JA, DeHaven RN, Taulane JP, Goodman M.

J Med Chem. 2002 Aug 15;45(17):3746-54. Erratum in: J Med Chem 2002 Nov 21;45(24):5414.

PMID:
12166947
34.

Arylacetamides as peripherally restricted kappa opioid receptor agonists.

Kumar V, Marella MA, Cortes-Burgos L, Chang AC, Cassel JA, Daubert JD, DeHaven RN, DeHaven-Hudkins DL, Gottshall SL, Mansson E, Maycock AL.

Bioorg Med Chem Lett. 2000 Nov 20;10(22):2567-70.

PMID:
11086731
35.

Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.

DeHaven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, Nagasaka H, Yu G, Yaksh T.

J Pharmacol Exp Ther. 1999 Apr;289(1):494-502.

PMID:
10087042
36.

Endomorphins fully activate a cloned human mu opioid receptor.

Gong J, Strong JA, Zhang S, Yue X, DeHaven RN, Daubert JD, Cassel JA, Yu G, Mansson E, Yu L.

FEBS Lett. 1998 Nov 13;439(1-2):152-6.

Supplemental Content

Loading ...
Support Center